SKINMED® TRIPLELOCK® ROSACEA PROTOCOL
SkinMed® Rosacea TripleLock® is a preferred treatment choice of Professor Tony Chu
Professor and Senior Lecturer, Imperial College London and President of the Acne & Rosacea Association UK

How common is Rosacea?
Rosacea affects around 1 in 10 adults, which equates to around 5 million people suffering from rosacea in the UK alone, around 4 million of which fall into the target audience of most aesthetic clinical practices.

The Science and the Solution
SkinMed® Synchorose® Formula is medically licensed for the treatment of Rosacea, and clinically proven to address all visible symptoms and underlying triggers using a unique combination of 4 key active ingredients. These work synergistically to build up the skin’s tolerance to internal and external triggers, short-circuiting reddening reactions as they occur while also working to reduce inflammation and irritation. SkinMed® have added fast erythema reducing ingredients and flushing receptor triggering inhibitors, with Rosacea Trigger Tolerance Threshold raising ingredients using key lipid boosters to reduce the incidence, depth and length of flushing episodes. SkinMed® retinoids are added to our SkinMed® Protocols to sustain results for the long term.

The Science and the Solution
SkinMed® Synchorose® Formula is medically licensed for the treatment of Rosacea, and clinically proven to address all visible symptoms and underlying triggers using a unique combination of 4 key active ingredients. These work synergistically to build up the skin’s tolerance to internal and external triggers, short-circuiting reddening reactions as they occur while also working to reduce inflammation and irritation. SkinMed® have added fast erythema reducing ingredients and flushing receptor triggering inhibitors, with Rosacea Trigger Tolerance Threshold raising ingredients using key lipid boosters to reduce the incidence, depth and length of flushing episodes. SkinMed® retinoids are added to our SkinMed® Protocols to sustain results for the long term.

How common is Rosacea?
Rosacea affects around 1 in 10 adults, which equates to around 5 million people suffering from rosacea in the UK alone, around 4 million of which fall into the target audience of most aesthetic clinical practices.

Outstanding results
Clinical trials involved rosacea sufferers who were part of the Rosacea Support Group, all of whom were long-standing sufferers who had tried almost everything else available on the market. After just 8 weeks, an astonishing 75% of these patients with difficult to treat symptoms found the products successful in managing their rosacea, proving SkinMed® Synchrorose® to be more effective than antibiotics

The Complete SkinMed® Rosacea Protocol
The complete SkinMed® TripleLock® Rosacea Protocol combines SkinMed® Synchrorose® with SkinMed® Tebiskin®, SkinMed® SkinVital® and SkinMed® EnerPeel® MA, forming an all-encompassing treatment that not only addresses the triggers and symptoms of Rosacea but improves the functionality of partially damaged and dilated blood vessels to function better and contract, due to the vasoconstrictive effect of SkinMed® EnerPeel® MA.

The Complete SkinMed® Rosacea Protocol
The complete SkinMed® TripleLock® Rosacea Protocol combines SkinMed® Synchrorose® with SkinMed® Tebiskin®, SkinMed® SkinVital® and SkinMed® EnerPeel® MA, forming an all-encompassing treatment that not only addresses the triggers and symptoms of Rosacea but improves the functionality of partially damaged and dilated blood vessels to function better and contract, due to the vasoconstrictive effect of SkinMed® EnerPeel® MA.

Outstanding results
Clinical trials involved rosacea sufferers who were part of the Rosacea Support Group, all of whom were long-standing sufferers who had tried almost everything else available on the market. After just 8 weeks, an astonishing 75% of these patients with difficult to treat symptoms found the products successful in managing their rosacea, proving SkinMed® Synchrorose® to be more effective than antibiotics
Please click on the booklet below to read more on our Amazing Protocols.
Use The Instruction Bar Below to Scroll pages, Zoom in, Or Full Page.
Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.
SkinMed ® Clinical Enerpeel Treatments recommended for successfully delivering this protocol include
EnerPeel® MA
EnerPeel® MA works synergistically alongside our all-encompassing SkinMed® Rosacea TripleLock® products to create the complete protocol, raising the skins’ trigger tolerance threshold (TTT) and short-circuiting flushing episodes, reducing the appearance of thread veins. EnerPeel® MA is medically licensed to treat vascular rosacea.
The Expert Know About Us
Just read what they have to say
KISHAN RAICHURA – COSMETIC DOCTOR AND DENTAL SURGEON